N. Shah

P. Hari, M. Pasquini, M. Horowitz, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non‐MALT Histologies

B. Erickson, P. Hari, M. Siker, 2017, Clinical lymphoma, myeloma & leukemia.

Acute promyelocytic leukemia presenting as a paraspinal mass.

A. Bagg, A. Perl, S. Luger, 2016, The Journal of community and supportive oncology.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

R. Vij, W. Wood, M. Aljurf, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis.

Aliki Taylor, M. Akbari, N. Shah, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.

P. Hari, M. Pasquini, B. Shaw, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric antigen receptor modified T cell therapy in B cell non‐Hodgkin lymphomas

N. Shah, A. Levin, 2019, American journal of hematology.

Bispecific CAR T-cells for B-cell Malignancies

N. Shah, F. Furqan, 2022, Expert opinion on biological therapy.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

S. Grupp, D. Porter, B. Levine, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

A. Szabo, N. Shah, M. Hamadani, 2019, The oncologist.

Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?

P. Hari, Bryon D Johnson, N. Shah, 2021, Cytotherapy.

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

T. Braun, P. Hari, M. Pasquini, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

K. Ahn, N. Shah, M. Hamadani, 2020, Blood.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

J. Vose, Sonali M. Smith, R. Vij, 2018, Cancer.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

R. Gale, H. Khoury, U. Popat, 2018, Blood advances.

Atypical Neuroleptic Malignant Syndrome: Pitfalls and Challenges in the Delirious Substance Abuser

H. Rosenberg, N. Shah, Mikhail Litinski, 2012 .

Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.

P. Armand, S. Schuster, C. Andreadis, 2019, The oncologist.

R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

J. Vose, N. Ghosh, A. Szabo, 2018, British journal of haematology.

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

D. Torigian, D. Porter, C. June, 2018, Cytotherapy.

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

Heather B. Gonzalez, John D. Davis, Travis J. Bernardo, 2022, The Lancet Infectious Diseases.

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

P. Hari, Bryon D Johnson, N. Shah, 2020, Blood advances.

Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome.

A. Banerjee, P. Hari, M. Pasquini, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.

A. Szabo, A. Cashen, N. Shah, 2019, Blood advances.

Perspective: An International Fludarabine shortage: Supply Chain Issues Impacting Transplant and Immune Effector Cell Therapy Delivery.

D. Miklos, R. Maziarz, Amber H Diaz, 2022, Transplantation and cellular therapy.

Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities

M. Norkin, M. Perales, M. Horowitz, 2020 .

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial.

M. Arbushites, M. Perales, H. Khoury, 2020, Blood.

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS

S. Schuster, A. Mato, R. Reshef, 2017, International journal of hematologic oncology.

Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis

A. Harrington, N. Shah, N. Epperla, 2016, American journal of hematology.

Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.

A. Szabo, Saira S Ahmed, A. Cashen, 2020, Blood advances.

What is the standard of care for primary mediastinal B cell lymphoma; R‐CHOP or DA‐EPOCH‐R? – Response to Melani et al

J. Svoboda, N. Shah, M. Hamadani, 2019, British journal of haematology.

Plasmacytic post‐transplant lymphoproliferative disorder: a case series of nine patients

S. Schuster, M. Karuturi, V. Ahya, 2013, Transplant international : official journal of the European Society for Organ Transplantation.

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.

V. Lazarevic, Yi-Bin Chen, Aliki Taylor, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.

A. Krishnan, A. Viswabandya, Z. DeFilipp, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease

P. Hari, M. Pasquini, M. Horowitz, 2018, Haematologica.

Associations between socioeconomic status and bispecific LV20.19 CAR T cell therapy outcomes.

Bryon D Johnson, A. Szabo, C. Hillard, 2021, Haematologica.

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol

Carol L. Williams, P. Hari, A. Szabo, 2022, The Yale journal of biology and medicine.

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells

P. Hari, Bryon D Johnson, A. Szabo, 2022, American journal of hematology.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A. Logan, D. Howard, J. Liesveld, 2021, Blood.

Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia.

P. Hari, Bryon D Johnson, N. Shah, 2020, JCO oncology practice.

Daratumumab in Primary Effusion Lymphoma.

A. Singavi, A. Harrington, N. Shah, 2018, The New England journal of medicine.

Alpha‐1‐antitrypsin for the treatment of steroid‐refractory acute gastrointestinal graft‐versus‐host disease

P. Hari, M. Pasquini, B. Shaw, 2017, American journal of hematology.

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective

P. Hari, M. Pasquini, B. Shaw, 2018, Bone Marrow Transplantation.

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

L. Lekakis, N. Ghosh, H. Lazarus, 2019, Journal of Hematology & Oncology.

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy

P. Hari, Edward Hackett, S. Cole, 2022, Communications Medicine.

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

D. Miklos, K. Flynn, L. Muffly, 2021, Blood.

Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study

D. Miklos, K. Flynn, L. Muffly, 2021, Blood.

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

W. Wierda, A. Mato, M. Yin, 2021, Hematological Oncology.

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Michael L. Wang, A. Alencar, I. Flinn, 2021, The Lancet.

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

P. Hari, M. Pasquini, N. Shah, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

P. Hari, N. Shah, T. Maatman, 2019, Front. Oncol..

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

CAR T-cell therapy for secondary CNS DLBCL

N. Shah, M. Hamadani, Gulrayz Ahmed, 2021, Blood advances.

Allogenic Transplant for Non-Hodgkin Lymphoma

N. Shah, Ravi Narra, 2019, Hematopoietic Cell Transplantation for Malignant Conditions.

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

P. Hari, S. Tarima, A. D’Souza, 2021, Clinical lymphoma, myeloma & leukemia.

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis

P. Hari, B. Shaw, A. Szabo, 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplant cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial.

M. Norkin, M. Perales, J. Pidala, 2022, Transplantation and cellular therapy.

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

M. Norkin, M. Perales, M. Horowitz, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation.

P. Hari, M. Pasquini, A. Szabo, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

N. Ledeboer, A. D’Souza, N. Shah, 2022, Cancer Cell.

BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naïve mantle cell lymphoma.

A. Ruppert, M. Dreyling, C. Cheah, 2022, Future oncology.

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress).

Michael L. Wang, M. Dreyling, C. Cheah, 2021, Clinical lymphoma, myeloma & leukemia.

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.

P. Hari, M. Pasquini, B. Shaw, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

B. Cheson, A. Schuh, C. Nabhan, 2019, Clinical Cancer Research.

Improving the Safety of Oral Chemotherapy at an Academic Medical Center.

L. Schuchter, T. Gangadhar, S. McGettigan, 2016, Journal of oncology practice.

Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Matthew J. Frigault, D. Teachey, M. Perales, 2023, Transplantation and cellular therapy.

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Sonali M. Smith, R. Vij, W. Wood, 2019, Blood Cancer Journal.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

A. Zelenetz, B. Cheson, T. Burns, 2018, Haematologica.

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

B. Cheson, J. Pagel, C. Tam, 2020, Blood and lymphatic cancer : targets and therapy.

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study

R. Foà, S. Molica, M. Vignetti, 2020, Cancer medicine.

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

A. Alencar, O. Abdel-Wahab, M. Davids, 2020 .

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

P. Hari, M. Pasquini, A. D’Souza, 2019, Blood Cancer Journal.

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.

M. Pasquini, A. D’Souza, N. Shah, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.

P. Hari, A. Szabo, A. D’Souza, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Sonali M. Smith, P. Armand, S. Jaglowski, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.

P. Hari, D. Schneider, N. Shah, 2022, Cytotherapy.

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

P. Hari, D. Schneider, N. Shah, 2021, Blood.

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

P. Hari, S. Malarkannan, D. Schneider, 2020 .

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

J. Briones, I. Flinn, U. Jaeger, 2021, Blood.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

F. Awan, M. Perales, C. Jacobson, 2022, Haematologica.

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.

P. Hari, N. Shah, M. Hamadani, 2022, JAMA oncology.

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

L. Gordon, J. Winter, S. Chowdhury, 2021, Blood.

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

L. Gordon, J. Winter, S. Chowdhury, 2022, Blood advances.

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response

P. Hari, John M. Astle, N. Shah, 2021, Haematologica.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, A. Zelenetz, I. Flinn, 2022, Blood.

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.

Sonali M. Smith, Z. DeFilipp, H. Lazarus, 2018, Blood advances.

Cellular Therapy

V. Radhakrishnan, N. Shah, P. Hari, 2020, Contemporary Bone Marrow Transplantation.

Severity of cytokine release syndrome and its association with infections after T-cell replete haploidentical related donor transplantation.

M. Graham, P. Hari, M. Pasquini, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

M. Pasquini, J. Wingard, K. Ballen, 2019, Blood advances.

Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes.

P. Hari, M. Pasquini, B. Shaw, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Yi-Bin Chen, S. Devine, C. Cutler, 2019, Blood advances.

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.

P. Hari, M. Pasquini, A. Szabo, 2019, JAMA network open.

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.

N. Kröger, P. Hari, D. Blaise, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

B. Sandmaier, M. Perales, A. Nagler, 2020, Blood advances.

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

M. Norkin, M. Perales, M. Horowitz, 2020 .

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

M. Pasquini, J. Wingard, K. Ballen, 2018, Blood.

Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis

John M. Astle, N. Shah, J. Zurko, 2021, Case reports in hematology.

CAR-T Cell Production Using the Clinimacs® Prodigy System

P. Hari, R. Orentas, D. Schneider, 2016 .

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

S. Dave, G. Bhagat, F. Hernandez-Ilizaliturri, 2021, Blood.

Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes.

D. Porter, N. Mitra, M. Schapira, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination

Nicholas R. Waters, P. Hari, M. V. D. van den Brink, 2022, medRxiv.

Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

B. Cheson, T. Burns, C. Nabhan, 2017 .

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

J. Burke, J. Leonard, A. Krishnan, 2020 .

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Parameswaran Hari, Mehdi Hamadani, Dina Schneider, 2018, Blood.

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

A. Alencar, C. Tam, B. Nair, 2022, Blood.

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

M. Arbushites, M. Perales, P. Chevallier, 2020 .

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

N. Shah, M. Hamadani, T. Fenske, 2022, Blood advances.

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion

Jess F. Peterson, N. Shah, H. Olteanu, 2017, Clinical case reports.

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation

P. Hari, M. Horowitz, S. Cole, 2018, BMC cancer.

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

T. Braun, P. Hari, M. Pasquini, 2017 .

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

L. Gordon, J. Winter, S. Chowdhury, 2021, Blood.

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

L. Gordon, J. Winter, A. Evens, 2020 .

Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial

B. Cheson, C. Nabhan, J. Pagel, 2018, American journal of hematology.

Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss.

N. Shah, F. Furqan, 2022, Annual review of medicine.

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

P. Riedell, D. Maloney, D. Brander, 2023, The Lancet.

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

P. Hari, D. Schneider, N. Shah, 2021, Blood.

Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.

P. Hari, R. Orentas, A. Worden, 2019, Journal of Clinical Oncology.

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

P. Hari, N. Shah, M. Hamadani, 2019, Leukemia & lymphoma.

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Clinical Lymphoma Myeloma and Leukemia.

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

P. Hari, D. Schneider, N. Shah, 2022, Blood.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Blood.

Abstract CT138: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study

Jennifer R. Brown, B. Nair, C. Cheah, 2022, Cancer Research.

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma

D. Torigian, J. Plastaras, E. Glatstein, 2014, Cancer medicine.

Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

N. Shah, M. Hamadani, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells.

G. Opiteck, V. Kaimal, Thomas Pertel, 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial

M. Arbushites, M. Perales, F. Dawkins, 2019, Biology of Blood and Marrow Transplantation.

Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis.

D. Frank, J. Svoboda, N. Shah, 2014, Clinical lymphoma, myeloma & leukemia.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

J. Briones, I. Flinn, D. Blaise, 2023, Cancer discovery.

Chimeric antigen receptor modified T cell therapy in B cell non‐Hodgkin lymphomas

N. Shah, Adam Levin, 2019, American journal of hematology.

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.

A. D’Souza, N. Shah, M. Hamadani, 2022, Clinical lymphoma, myeloma & leukemia.

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

S. Barta, J. Svoboda, Mengyang Di, 2023, Blood advances.

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

A. Alencar, A. Zelenetz, I. Flinn, 2023, Journal of Clinical Oncology.

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.

Sonali M. Smith, J. Bolaños-Meade, Z. DeFilipp, 2018, Blood advances.

Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis Is an Effective Surveillance Tool in Patients with Mantle Cell Lymphoma

N. Shah, M. Hamadani, T. Fenske, 2022, Blood.

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

M. Arbushites, M. Perales, H. Khoury, 2018, Blood.

Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.

C. Cheah, Yucai Wang, W. Jurczak, 2023, Journal of Clinical Oncology.